Screening women with dense breasts with both molecular breast imaging (MBI) and digital breast tomosynthesis (DBT) significantly increased the detection of invasive cancers compared with DBT alone, according to a major multicenter trial published in Radiology.

The study, known as the Density MATTERS (Molecular Breast Imaging and Tomosynthesis to Eliminate the Reservoir) trial, is the first prospective, multicenter evaluation of MBI as a supplement to DBT in women with dense breasts. It was led by Carrie B. Hruska, PhD, professor of medical physics at Mayo Clinic, and included participants from five U.S. screening sites.

“Someone who’s having their routine annual screen every year should not be diagnosed with advanced breast cancer. That’s just unacceptable,” Hruska said. “With a supp

See Full Page